Researchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains that closely mirror the one recently detected in cows, chickens and one person in Texas.
Researchers at Texas Biomed collaborate with teams at UC Santa Cruz and Brigham Young University to verify the new diagnostic system, which combines optofluidics and nanopores, accurately tests for COVID-19 and Zika virus.
Texas Biomedical Research Institute has created a new global center to foster collaborations in infectious disease research. The International Center for the Advancement of Research & Education (I·CARE) leverages the power of global exchange to solve complex health issues in an increasingly connected world.
A DNA-based vaccine is very effective at protecting against COVID-19, according to a joint preclinical study by Scancell Ltd and Texas Biomedical Research Institute (Texas Biomed) recently published in the Journal of Biotechnology and Biomedicine.
Researchers in New York and Texas have identified that female marmosets are more likely to transmit the Zika virus during pregnancy if they have been previously infected by a different virus, dengue.
Researchers at Texas Biomedical Research Institute have succeeded in generating the lung’s most important immune cell, the alveolar macrophage, in the lab.
How malaria parasites evolved to evade a major antimalarial drug has long been thought to involve only one key gene. Now, thanks to a combination of field and lab studies, an international research team has shown a second key gene is also involved in malaria’s resistance to the drug chloroquine.
A new software tool developed by Texas Biomedical Research Institute and collaborators can help scientists and vaccine developers quickly edit genetic blueprints of pathogens to make them less harmful. The tool, called CoDe – short for Codon Deoptimization – enables users to make precise edits to a genetic code to make genes less functional – in other words, to deoptimize the genes.
The National Institutes of Health has awarded $3.8 million to Texas Biomedical Research Institute to further develop a promising HIV vaccine candidate that stops the virus upon entry, before it begins rapidly spreading throughout the body.
A Sudan ebolavirus vaccine and antibody therapeutic tested at Texas Biomedical Research Institute have been sent to Uganda as part of efforts to control the outbreak there.
The federal agency that protects against pandemics and bioterrorism has elevated Texas Biomedical Research Institute into the top ranks of its national readiness and preparedness network. The new designation as a prime contractor opens Texas Biomed to a portfolio of up to $100 million in funding over five years through the Biomedical Advanced Research and Development Authority (BARDA).
Texas Biomed will help map the developing brain with unprecedented detail for the National Institutes of Health’s BRAIN Initiative Cell Atlas Network (BICAN). NIH recently awarded a total of $500 million to 11 teams that will work together to build a 3D brain atlas at single cell resolution over the next five years.
NIH’s National Institute of Allergy and Infectious Diseases awarded Texas Biomedical Research Institute and The Access to Advanced Health Institute in Seattle, Washington, a $3.5 million, five-year Innovation for Tuberculosis Vaccine Discovery grant.
A modified tuberculosis (TB) vaccine developed at Texas Biomed could help treat a form of bladder cancer, called non-muscle invasive bladder cancer, without strong side effects. Results in mouse models and human cells show promising results and pave the way for human clinical trials. The research, conducted in close collaboration with UT Health San Antonio, was published online in June in the journal Cancer Immunology, Immunotherapy.
Texas Biomed has received a $3.9 million NIH grant to explore how gene-editing technology may help eradicate HIV in the brain.
Researchers at Texas Biomed have received approval to work with a weakened, non-harmful version of SARS-CoV-2 in biosafety level 2 (BSL-2) laboratories, which makes it safer, faster and easier to study the virus, its mutations, and to identify new treatments for COVID-19.
Texas Biomedical Research Institute Professor Luis Martinez-Sobrido, PhD, an expert in virology, vaccines and antiviral research, has been recruited to collaborate with three of the nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern announced by NIH this spring.
A new software tool makes it easier to study relationships between a host, its microbiome and pathogens like HIV or SARS-CoV-2.
The $5.8 million center at Texas Biomed is one of the inaugural Interdisciplinary NexGen TB Research Advancement Centers (IN-TRAC) funded by the U.S. National Institute of Allergy and Infectious Diseases.
Researchers at Texas Biomed and University of Alabama at Birmingham discovered an antibody cocktail against COVID-19 that appears effective against all variants and other coronaviruses. The cocktail has been exclusively licensed to Aridis Pharmaceuticals, which is seeking a manufacturing partner to advance the treatment to human clinical trials.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right